Who
Debra Zack
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Spero Therapeutics; Chief Medical Officer, Exagen.
In numbers
- Trades disclosed
- 9
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 24 Mar 2020
- Last trade
- 3 Aug 2026
- Last filed
- 6 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 6 Aug 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —162,311 at $0.00 | filing |
| 3 Aug 2026filed 6 Aug 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —324,675 at $0.00 | filing |
| 3 Aug 2026filed 6 Aug 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —324,675 at $0.00 | filing |
| 3 Aug 2026filed 6 Aug 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —162,311 at $0.00 | filing |
| 1 Mar 2022filed 2 Mar 2022 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code F | $23K3,241 at $7.12 | filing |
| 4 Feb 2022filed 8 Feb 2022 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | XGN ExagenDiagnostics & Labs | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 24 Mar 2020filed 26 Mar 2020 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.